Literature DB >> 7784108

Phantom limb pain: are cutaneous nociceptors and spinothalamic neurons involved in the signaling and maintenance of spontaneous and touch-evoked pain? A case report.

R Baron1, C Maier.   

Abstract

A patient suffered multiple fractures of the right leg and a left brain-stem infarction involving the anterolateral fasciculus of the central nociceptive system following multiple trauma. Later, the right leg was amputated, resulting in spontaneous and touch-evoked phantom pain and mechanical stump allodynia. However, quantitative sensory testing revealed considerable impairment of sensations normally mediated by cutaneous nociceptors and central spinothalamic systems on the right body side, including the stump but nearly intact touch and vibration senses. Quantitative assessment of peripheral nociceptive C-fiber function (axon reflex vasodilatation and flare) showed no abnormalities on both sides. Sympathetic blocks did not change spontaneous and evoked pain. Epidural and spinal anesthesia abolished evoked pain but had no effect on spontaneous phantom pain. Extirpation of a neuroma of the sciatic nerve did not alter spontaneous and evoked pain. TENS resulted in an increase in pain. We concluded the following. (i) Painful somatosensory memories that are responsible for phantom limb pain are located in the brain, most probably in the thalamus or cortex. (ii) Touch-evoked phantom pain and stump allodynia are not mediated by cutaneous nociceptive C and A delta fibers and spinal nociceptive pathways (spinothalamic tract). Activity in the lemniscal system (low-threshold mechanoreceptive A beta afferents, dorsal columns and medial lemnicus system) may be transferred to central pain signaling neurons in the thalamus or cortex resulting in touch-evoked pain sensations. (iii) Ongoing activity in cutaneous nociceptive C fibers and spinal nociceptive systems is not necessary to maintain central processes that account for spontaneous and touch-evoked pain sensations. Activity in nociceptors of deep somatic tissues might be more important.

Entities:  

Mesh:

Year:  1995        PMID: 7784108     DOI: 10.1016/0304-3959(94)00188-K

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  8 in total

Review 1.  Optimal treatment of phantom limb pain in the elderly.

Authors:  R Baron; G Wasner; V Lindner
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

2.  [Referred pain from amputation stump trigger points into the phantom limb].

Authors:  K-U Kern; C Martin; S Scheicher; H Müller
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

3.  A novel curcumin derivative for the treatment of diabetic neuropathy.

Authors:  Daniel J Daugherty; Alexandra Marquez; Nigel A Calcutt; David Schubert
Journal:  Neuropharmacology       Date:  2017-11-06       Impact factor: 5.250

4.  Potentiation of sensory responses in the anterior cingulate cortex following digit amputation in the anaesthetised rat.

Authors:  F Wei; M Zhuo
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

Review 5.  Noninvasive Brain Stimulation, Maladaptive Plasticity, and Bayesian Analysis in Phantom Limb Pain.

Authors:  Leon Morales-Quezada
Journal:  Med Acupunct       Date:  2017-08-01

6.  [Effect of botulinum toxin type B on residual limb sweating and pain. Is there a chance for indirect phantom pain reduction by improved prosthesis use?].

Authors:  K-U Kern; M Kohl; U Seifert; T Schlereth
Journal:  Schmerz       Date:  2012-04       Impact factor: 1.107

7.  [Prevalence and risk factors of phantom limb pain and phantom limb sensations in Germany. A nationwide field survey].

Authors:  U Kern; V Busch; M Rockland; M Kohl; F Birklein
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

8.  The Role of Capsaicin-induced Acute Inactivation of C-fibers on Tactile Learning in Rat.

Authors:  Mohammadreza Rahmani; Soodeh Rajabi; Mohammad Allahtavakoli; Ali Roohbakhsh; Vahid Sheibani; Ali Shamsizadeh
Journal:  Iran J Basic Med Sci       Date:  2013-02       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.